Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lithium shows promise for autism social deficits in small trial

NCT ID NCT04623398

Completed Symptom relief Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested whether lithium can improve social communication in children with autism spectrum disorder who also have a SHANK3 gene mutation (Phelan-McDermid syndrome). 22 children took either lithium or a placebo for 12 weeks. Researchers measured changes in social responsiveness. The goal was to see if lithium, identified from lab studies on patient-derived stem cells, could ease core autism symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lithium carbonate
What this could lead to
If it works, this could point toward a treatment for social communication deficits in people with autism linked to SHANK3 mutations.
What could go wrong
This was a very small pilot study with only 22 participants. Results may not apply to everyone, and lithium can have side effects like kidney or thyroid issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autism autism spectrum disorder Phelan-McDermid syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTISM SPECTRUM DISORDER

Contacts and locations

Locations

  • Hôpital Robert Debré

    Paris, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.